Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00767650 · ClinicalTrials.gov registry record
Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic Anemia
A clinical trial of Aplastic Anemia, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- 7
- Enrollment target
- 1
- Study location
NCT00767650: Completed study of Aplastic Anemia, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT00767650 is a study of Aplastic Anemia that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 7 participants, below the 42-participant average among 23 other Aplastic Anemia trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00767650, a study of Aplastic Anemia, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will use neuropsychological tests to look at nervous system side effects of Cyclosporine (CsA) in patients with aplastic anemia. CsA is used as part of an immunosuppressive regimen in treating severe aplastic anemia. The drug can produce nervous system side effects, such as tremor and, less commonly, insomnia, anxiety, headache, confusion or seizures. This study will look at effects of CsA on intellectual ability, depression, anxiety, attention, concentration, memory, perception, coordination, and thought processing in patients Patients 15 years of age or older who have severe aplastic anemia may be eligible for this study if they: * are co-enrolled in a Clinical Center protocol in which they will receive CsA * have not taken CsA for 6 months before enrolling in this study Participants undergo neuropsychological testing. In addition, they provide blood samples and their clinical data are reviewed for things that may influence the interpretation of findings from the testing, such as results of blood tests, types of medications taken, number of transfusions required, etc. The procedures are as follows: Before first dose of cyclosporine: * Patients are asked about prior problems with their nervous system, prior treatment for their aplastic anemia (including transfusions), prior infections, and current medications. They then complete the following sets of tests: * Battery 1: A set of three tests that measure intellectual ability, level of depression (if any) and level of anxiety (if any). * Battery 2: A set of seven tests that measure changes in the central nervous system and how these changes affect attention, concentration, memory, perception, coordination, and thought processing. * Patients provide a half teaspoon of blood for this study at the same time blood is collected for their primary treatment protocol. 6 months and 12 months after starting cyclosporine * Patients are asked about treatment for their aplastic anemia (including transfusions),
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-09-23 |
| Est. Completion | 2011-06-28 |
What the finished NCT00767650 record still lists
NCT00767650 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 42-participant average among 23 other Aplastic Anemia trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Aplastic Anemia appearing as the primary indexed condition, and to 0 interventions.
NCT00767650 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00767650 about?
NCT00767650 is a clinical study titled "Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic Anemia". This study will use neuropsychological tests to look at nervous system side effects of Cyclosporine (CsA) in patients with aplastic anemia. CsA is used as part of an immunosuppressive regimen in treating severe aplastic anemia. The drug can produce nervous system side effects, such as tremor and, le...
What is the current status of trial NCT00767650?
This trial is currently completed. The enrollment target is 7 participants. The study started on 2008-09-23. Estimated completion is 2011-06-28.
What conditions does trial NCT00767650 study?
This clinical trial studies the following conditions: Aplastic Anemia.
Who is sponsoring clinical trial NCT00767650?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00767650 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aplastic Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00767650's enrollment target sits among peer trials
7 23rd of 23 higher than 1 of 23 other Aplastic Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aplastic Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
RECRUITING · NA
-
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
RECRUITING · Phase 2
-
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RECRUITING · Early Phase 1
-
Two Step Haplo With Radiation Conditioning
RECRUITING · Phase 2
-
Umbilical Cord Blood Transplantation From Unrelated Donors
RECRUITING
-
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI